AGLE News and Press, Aeglea BioTherapeutics Inc. From 10/02/23

Aeglea BioTherapeutics Announces Grants of Inducement Awards PR Newswire WALTHAM, Mass. , Oct. 2, 2023 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. ("Aeglea") (NASDAQ: AGLE), a biotechnology company advancing a pipeline of antibody therapeutics with the potential...

Aeglea BioTherapeutics to Participate in Upcoming September Conference PR Newswire WALTHAM, Mass. , Sept. 14, 2023 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. ("Aeglea") (Nasdaq: AGLE), a biotechnology company advancing a pipeline of antibody therapeutics w...

Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE) is one of today's top gainers. The company's shares are currently up -1.98% on the day to $14.72. Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients and f...

Aeglea BioTherapeutics Announces Reverse Stock Split PR Newswire WALTHAM, Mass. , Sept. 7, 2023 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. ("Aeglea") (Nasdaq: AGLE), a biotechnology company advancing a pipeline of antibody therapeutics with the potential to tra...

2023-09-05 11:24:21 ET More on Aeglea BioTherapeutics Seeking Alpha’s Quant Rating on Aeglea BioTherapeutics Historical earnings data for Aeglea BioTherapeutics Financial information for Aeglea BioTherapeutics Aeglea initiated with Buy at Stifel citing...

2023-08-31 03:30:52 ET Summary Baker Brothers' 13F portfolio value decreased from $18.38B to $17.28B. The largest five stakes in the portfolio are Seagen, Incyte, BeiGene, ACADIA Pharmaceuticals, and Madrigal Pharmaceuticals, making up around 83% of the portfolio. Baker Brothe...

2023-08-11 10:25:25 ET Aeglea BioTherapeutics press release ( NASDAQ: AGLE ): Q2 GAAP EPS of -$2.27. $236.7 million of cash and cash equivalents and restricted cash as of June 30, 2023 For further details see: Aeglea BioTherapeutics GAAP EPS of -$2.27

Aeglea BioTherapeutics Reports Second Quarter 2023 Financial Results PR Newswire Acquisition of Spyre's assets and concurrent oversubscribed $210.0 million private investment positions the company to advance a potentially best-in-class inflammatory bowel disease (IBD) port...

Aeglea BioTherapeutics Announces Sale of Pegzilarginase to Immedica Pharma PR Newswire Global rights to pegzilarginase in development for Arginase 1 Deficiency sold to Immedica Pharma for $15 million upfront cash proceeds and up to $100 million of contingent milestone ...

2023-07-25 15:23:05 ET Aeglea BioTherapeutics ( NASDAQ: AGLE ) traded higher on Tuesday after Stifel launched its coverage with a Buy recommendation citing its potential against inflammatory bowel disorders, ulcerative colitis, and Crohn's disease. Despite rising competition amo...